vemurafenib
NCI Pediatric MATCH Trial Interim Data Shows 24 Percent of Patients Eligible for Targeted Therapy
Premium
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
Genentech's Zelboraf Gets FDA Approval in BRAF Mutation-Positive Erdheim-Chester Disease
This is the first US Food and Drug Administration approval for a drug based solely on data from a basket study.
BRAF Inhibitor Resistance Mutations Identified
By comparing pre-treatment and post-relapse samples from vemurafenib-treated melanoma patients, researchers uncovered resistance-related cohesin complex mutations.